Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 6, Number 6—December 2000

Perspective

Evidence Against Rapid Emergence of Praziquantel Resistance in Schistosoma haematobium, Kenya

Charles H. King*, Eric M. Muchiri†, and John H. Ouma†
Author affiliations: *Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, Ohio, USA; †Ministry of Health, Nairobi, Kenya

Main Article

Table 1

Effectiveness of praziquantel (PZQ) in eliminating Schistosoma haematobium infection, Msambweni, Coast Province, Kenya, 1984–1992

Patient's infection and treatment status 1984 1985 1986 1987 1989 1990 1991
Egg-positive urine,
Given PZQ, never previously treated 17%
(97 to 1.5)
n = 981 12%
(33 to 1.5)
n = 51 34%
(29 to 3.7)
n = 82 - 15%
(18 to 1.5)
n = 352 4%
(22 to 1.1)
n = 292 35%
(24 to 4)
n = 274
Egg-positive urine,
Given PZQ, had 1 PZQ treatments - 13%
(10 to 1.5)
n = 111 38%
(16 to 2.6)
n = 47 - 10%
(19 to 1.1)
n = 68 2%
(14 to 1.0)
n = 73 29%
(13 to 2.8)
n = 64
All egg-positive, PZQ-treated patients 17%
(97 to 1.5)
n = 981 13%
(15 to 1.5)
n = 162 35%
(24 to 3.3)
n = 129 - 14%
(19 to 1.4)
n = 420 4%
(20 to 1.1)
n = 365 34%
(22 to 3.8)
n = 338
Infection rate
(egg - to egg + conversion) 15% 9% 11% 11% 13% 10% 21%
All patients, treated and untreated 18%
n = 3,196 12%
n =2,498 14%
n = 2,372 19%
n = 1,968 14%
n = 1,398 13%
n = 2,579 24%
n = 1,938

aPZQ = praziquantel.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO